Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

作     者：Robert L Gottlieb 

作者机构：From Baylor University Medical Center and Baylor Scott and White Research Institute Dallas (R.L.G.) and Care United Research Forney (S.M.) — all in Texas the Nuren Medical and Research Center Miami (C.E.V.) Evolution Clinical Trials Hialeah Gardens (G.P.) the Midland Florida Clinical Research Center DeLand (G.O.) Luminous Clinical Research–South Florida Urgent Care Pembroke Pines (A.H.) and Triple O Research Institute Professional Association West Palm Beach (O.O.) — all in Florida Hospital Universitari Germans Trias i Pujol and IrsiCaixa AIDS Research Institute Barcelona (R.P.) and Hospital Universitario Infanta Leonor and Gregorio Marañón Health Research Institute Madrid (P.R.) — all in Spain the Cherokee Nation Outpatient Health Center Tahlequah OK (J.M.) Intermountain Healthcare (B.J.W. S.M.B.) and the University of Utah School of Medicine (S.M.B.) — both in Murray Copenhagen University Hospital–Rigshospitalet Copenhagen (B.U.N.) University College London Hospitals NHS Foundation Trust and the London School of Hygiene and Tropical Medicine — both in London (M.B.) the Institute of Liver Health Mesa AZ (Y.S.) Kaiser Permanente Oakland (J.S.) and Gilead Sciences Foster City (K.J. R.H.H. A.O. S.C. G.C. M.A. S.D. N.B.-R. F.D.) — both in California Brigham and Women’s Hospital and Harvard Medical School — both in Boston (F.M.M.) Johns Hopkins University School of Medicine Baltimore (M.J.K.) the University of Colorado School of Medicine Aurora (A.A.G.) and the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine — both in Seattle (J.T.S. J.A.H.).Dr. Gottlieb can be contacted at or at Baylor University Medical Center Center for Advanced Heart and Lung Disease 3410 Worth St. Ste. 250 Dallas TX 75246. Francisco M. Marty M.D. is deceased. A complete list of the GS-US-540-9012 (PINETREE) Investigators is provided in the Supplementary Appendix available at ***. 

出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)

年 卷 期：2021年第43卷第10期

页      面：1691-1691页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Gilead Sciences 

主　　题：clinical intravenous des 

摘      要：Background:Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019(Covid-19).Whether the use of remdesivir in symptomatic,nonhospitalized patients with Covid-19 who are at high risk for disease progression prevents hospitalization is ***:We conducted a randomized,double-blind,placebo-controlled trial involving nonhospitalized patients with Covid19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression(age≥60 years,obesity,or certain coexisting medical conditions).Patients were randomly assigned to receive intravenous remdesivir(200 mg on day 1 and 100 mg on days 2 and 3)or *** primary efficacy end point was a composite of Covid-19-related hospitalization or death from any cause by day *** primary safety end point was any adverse event.A secondary end point was a composite of a Covid-19-related medically attended visit or death from any cause by day 28.